Arcutis Biotherapeutics 

Yahoo Finance • 11 months ago

UPDATE 1-US FDA approves Arcutis' drug to treat chronic skin disease

(Adds details on the approved drug in paragraphs 2-4) Dec 15 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved Arcutis Biotherapeutics' drug for treating a skin condition called seborrheic dermatitis in individual... Full story

Yahoo Finance • 11 months ago

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

Arcutis Biotherapeutics, Inc. ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration of use ZO... Full story

Yahoo Finance • 11 months ago

FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

FDA has set a PDUFA target action date of July 07, 2024 Atopic dermatitis affects approximately 16.5 million adults and 9.6 million children in the United StatessNDA supported by positive efficacy and safety data from the pivotal Phase 3 I... Full story

Yahoo Finance • last year

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript November 3, 2023 Arcutis Biotherapeutics, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.9. Operator: Good day, and welcome to... Full story

Yahoo Finance • last year

Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update

Achieved total revenues of $38.1 million in the third quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $8.1 million, a 70% increase compared to the second quarter of 2023, driven by sequential improvement in... Full story

Yahoo Finance • last year

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today repor... Full story

Yahoo Finance • last year

Arcutis to Report Third Quarter 2023 Financial Results

WESTLAKE VILLAGE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that it will... Full story

Yahoo Finance • last year

New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials

Individual patient response data highlights 95% of individuals treated with ZORYVE had a measurable improvement in Psoriasis Area and Severity Index (PASI) at Week 8Over 85% achieved measurable improvement by Week 2 (the earliest timepoint... Full story

Yahoo Finance • last year

Arcutis Announces Pricing of $100 Million Public Offering

WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,... Full story

Yahoo Finance • last year

Arcutis Announces Proposed Public Offering

WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced t... Full story

Yahoo Finance • last year

Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress

Once-daily, steroid-free roflumilast foam 0.3% demonstrated significant improvements in both scalp and body psoriasis across all efficacy endpoints compared to vehicleNew data highlights a significant reduction in scalp itch observed as ea... Full story

Yahoo Finance • last year

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

WESTLAKE VILLAGE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today annou... Full story

Yahoo Finance • last year

Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

Industry veteran with deep commercial experience in dermatology and immunologyAyisha Jeter appointed Senior Vice President, Marketing and Market Access WESTLAKE VILLAGE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics... Full story

Yahoo Finance • last year

New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis

WESTLAKE VILLAGE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the launch o... Full story

Yahoo Finance • last year

Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trials For the primary endpoint, 25.4% of children treated once daily with roflumilast cream 0... Full story

Yahoo Finance • last year

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older

Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United StatesIn pivotal Phase 3 trials, roflumilast cream demonstrated statistically significant improvements... Full story

Yahoo Finance • last year

Arcutis to Present at Upcoming Investor Conference

WESTLAKE VILLAGE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis... Full story

Yahoo Finance • last year

11 Cheap Small-Cap Stocks to Buy Before the Next Breakout

In this piece, we will take a look at 11 cheap small cap stocks to buy before the next breakout. If you want to skip out on an introduction to small cap stocks and the latest events in the stock market, then take a look at 5 Cheap Small-Ca... Full story

Yahoo Finance • last year

Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%  

The Cream That Can is a direct-to-consumer ad highlighting that clear skin is possible with ZORYVE ZORYVE is a once-daily, steroid-free cream for individuals with plaque psoriasis 12 years and above that can be used for long-term treatment... Full story

Yahoo Finance • last year

Arcutis Appoints Interim Chief Financial Officer (CFO)

WESTLAKE VILLAGE, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today annou... Full story